The Center for Biosimilars® recaps the top news for the week of October 22, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 22.
Number 5: Genentech has announced this week that the FDA has approved an update to the label of its reference rituximab, sold as Rituxan.
Number 4: China-based drug maker Innovent Biologics has revealed that China’s National Medical Products Administration has approved its application to test a combination therapy comprising a proposed biosimilar bevacizumab product, plus sintilimab.
Number 3: During a presentation at the 5th DIA Biosimilars Conference in London, FDA’s Leah Christl provided an update on the Biosimilar Action Plan.
Number 2: Mylan recently announced that it has launched its biosimilar adalimumab, Hulio, in the European Union. Hulio’s entrance into the marketplace brings the number of available biosimilar adalimumab therapies to 4.
Number 1: Among European nations, Denmark has had some of the greatest success with leveraging biosimilars to reduce cost burdens on its healthcare system. During the 5th DIA Biosimilars Conference, stakeholders heard about how Denmark has achieved its strong biosimilar uptake.
Finally, last week, our e-newsletter asked if you thought that clinicians would be comfortable with off-label use of the proposed rituximab biosimilar, CT-P10.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.